JANSSEN BIOTECH Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN BIOTECH, and when can generic versions of JANSSEN BIOTECH drugs launch?
JANSSEN BIOTECH has five approved drugs.
There are thirty-five US patents protecting JANSSEN BIOTECH drugs.
There are eight hundred and thirty-three patent family members on JANSSEN BIOTECH drugs in sixty-one countries and seventy-three supplementary protection certificates in twenty countries.
Summary for JANSSEN BIOTECH
International Patents: | 833 |
US Patents: | 35 |
Tradenames: | 5 |
Ingredients: | 5 |
NDAs: | 5 |
Patent Litigation for JANSSEN BIOTECH: | See patent lawsuits for JANSSEN BIOTECH |
Drugs and US Patents for JANSSEN BIOTECH
Expired US Patents for JANSSEN BIOTECH
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Biotech | ZYTIGA | abiraterone acetate | TABLET;ORAL | 202379-001 | Apr 28, 2011 | 5,604,213 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN BIOTECH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
International Patents for JANSSEN BIOTECH Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2022201060 | ⤷ Subscribe |
South Korea | 102469506 | ⤷ Subscribe |
Hungary | E058219 | ⤷ Subscribe |
Australia | 2022291429 | ⤷ Subscribe |
Japan | 5466814 | ⤷ Subscribe |
South Korea | 20190110581 | ⤷ Subscribe |
European Patent Office | 3697398 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JANSSEN BIOTECH Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1633724 | 13/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
2240466 | 132018000000301 | Italy | ⤷ Subscribe | PRODUCT NAME: NIRAPARIB TOSILATO O UN SUO IDRATO, IN PARTICOLARE IL TOSILATO MONOIDRATO(ZEJULA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1235, 20171120 |
2240466 | 300938 | Netherlands | ⤷ Subscribe | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE |
2109608 | 122018000048 | Germany | ⤷ Subscribe | PRODUCT NAME: NIRAPARIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ, STEREOISOMER ODER TAUTOMER DAVON, EINSCHLIESSLICH DES TOSYLATS DAVON; REGISTRATION NO/DATE: EU/1/17/1235 20171116 |
2240466 | SPC/GB18/018 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: NIRAPARIB TOSYLATE OR A HYDRATE THEREOF, ESPECIALLY THE TOSYLATE MONOHYDRATE; REGISTERED: UK EU/1/17/1235 20171120; UK PLGB 19494/0294 20171120 |
2109608 | 667 | Finland | ⤷ Subscribe | |
2368550 | C201930040 | Spain | ⤷ Subscribe | PRODUCT NAME: APALUTAMIDA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1342; DATE OF AUTHORISATION: 20190114; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1342; DATE OF FIRST AUTHORISATION IN EEA: 20190114 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.